GAITHERSBURG, Md. (DC News Now) — AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a groundbreaking approach to fighting cancer.

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

After rising by over 20% since November, the AstraZeneca (AZN.L) share price is on a good run. And now management has just signed a $1bn deal to acquire EsoBiotec and further secure its long-term ...

Learn More. After rising by over 20% since November, the AstraZeneca (LSE:AZN) share price is on a good run. And now management has just signed a $1bn deal to acquire EsoBiotec and further secure ...

The companies expect the transaction to close during the second quarter of 2025. AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition EsoBiotec SA has entered into a ...

The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune WILMINGTON, Del., March 14, 2025--AstraZeneca and Erin Andrews have teamed up as part of a national public health ...

AZN to Acquire EsoBiotec; EU Nod for Imfinzi Expanded Use AstraZeneca announced a definitive agreement to acquire Belgium-based, EsoBiotec, a leading vivo cell therapy company for a total ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The UK ...